Continuous low plasma concentrations of everolimus provides equivalent efficacy to oral daily dosing in mouse xenograft models of human cancer.

Autor:	Laborde, Laurent, Oz, Fatos, Ristov, Mitko, Guthy, Daniel, Sterker, Dario, McSheehy, Paul
Předmět:	EVEROLIMUS DRUG toxicity BIOAVAILABILITY LEUKOCYTE count DRUG efficacy CANCER treatment THERAPEUTICS ANIMAL experimentation ANTINEOPLASTIC agents BREAST tumors COMPARATIVE studies DRUG administration KIDNEY tumors LACTIC acid LIQUID chromatography MASS spectrometry RESEARCH methodology MEDICAL cooperation MICE ORAL drug administration POLYESTERS RESEARCH EVALUATION research
Zdroj:	Cancer Chemotherapy & Pharmacology; Oct2017, Vol. 80 Issue 4, p869-878, 10p
Abstrakt:	Purpose: Everolimus is a drug used successfully in a number of different oncology indications, but significant on-target toxicities exist. We explored the possibility of improving the therapeutic index (TI) by studying alternative means of administering the drug based upon low continuous dosing.Methods: All studies were performed using naïve nude mice or nude mice bearing s.c. human renal 786-O tumours or human breast MDA-MB-468 tumours. Everolimus was administered via a standard emulsion, either i.v., p.o., i.p., s.c., or via s.c. osmotic mini-pumps (MP) or via poly-lactic-co-glycolic (PLGA)-microparticles (PLGA-µP) prepared from everolimus powder injected s.c. Total-drug levels in blood, plasma or tissues were quantified ex vivo by LC-MS/MS. Efficacy studies were performed over 2-3 weeks and toxicity assessed by changes in body weight, glucose and white blood cell count. Effects on tumour activity biomarkers were quantified using reverse-phase protein array.Results: Everolimus administration s.c. in an emulsion decreased the absorption rate but increased the C max and bio-availability of everolimus compared to standard approaches of administration p.o. or i.p. Everolimus administration s.c. via MP or PLGA-µP reduced the C max and provided continuous low concentrations of everolimus in the plasma, which inhibited tumour pS6/S6 to a similar degree to oral administration. Toxicities such as changes in body weight or white blood cell count were unaffected. Provided the everolimus concentration was above the free unbound IC50 for proliferation of the tumour cell line, efficacy could be achieved equivalent to that provided by standard oral administration. However, an overall improvement in the TI could not be demonstrated.Conclusions: Continuous low plasma concentrations of everolimus can provide strong efficacy in preclinical models, which if translatable to the clinic may reduce on-target toxicities and so increase the TI. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Full text from SpringerLink